Press Release


July 7, 2015

PCSK9 class could have major impact on budgets but lack of data and comparability of drugs will allow aggressive payers to control costs: RxScorecard™ analysis

According to Real Endpoints’ (RE) just-released RxScorecard™ analysis of the new lipid-lowering therapies, the innovative PCSK9 inhibitors which could be highly valuable for patients with difficult-to-lower, high LDL-C (bad cholesterol) levels, are both comparable to each other and lack key data that would justify broader use.

The implications: payers will have an extraordinary opportunity to control costs in this class, which many analysts have predicted could far surpass hepatitis C treatment costs.

read full press release >